Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
VeClose Five Year Follow-Up Extension Study
NCT03455699 · View on ClinicalTrials.gov ↗
Study Summary
The VeClose Five Year Follow-up Extension Study will seek to gain additional follow-up data from the patients enrolled in the VeClose study (NCT01807585).
Conditions Studied
Interventions
- DEVICE VenaSeal SCS
- DEVICE ClosureFast Radiofrequency Ablation (RFA)
- DEVICE Roll-In (VenaSeal SCS)
Study Locations (9)
Arizona
- Morrison Vein Institute — Scottsdale
California
- GBK Cosmetic Laser Dermatology — San Diego
Colorado
- Radiology Imaging Associates (RIA) — Greenwood Village
Illinois
- Prairie Education & Research Cooperative — Springfield
Maryland
- MD Laser Skin & Vein Institute — Hunt Valley
New York
- Vein Institute of Buffalo — North Tonawanda
Oregon
- Inovia Vein Speciality Center — Bend
Virginia
- Sentara Vascular Specialists — Virginia Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-01 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03455699
The ClinicalTrials.gov registry entry for NCT03455699 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Endovascular, which has 8 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Great Saphenous Vein (GSV) With Venous Reflux Disease appearing as the primary indexed condition, and to 3 interventions — of which VenaSeal SCS is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03455699 reports 9 study locations spanning 9 distinct geographic areas — top geographies include Arizona, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03455699 about?
NCT03455699 is a clinical study titled "VeClose Five Year Follow-Up Extension Study". The VeClose Five Year Follow-up Extension Study will seek to gain additional follow-up data from the patients enrolled in the VeClose study (NCT01807585).
What is the current status of trial NCT03455699?
This trial is currently completed. The enrollment target is 114 participants. The study started on 2016-07. Estimated completion is 2019-01.
What conditions does trial NCT03455699 study?
This clinical trial studies the following conditions: Great Saphenous Vein (GSV) With Venous Reflux Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03455699?
The interventions under investigation include: VenaSeal SCS (DEVICE), ClosureFast Radiofrequency Ablation (RFA) (DEVICE), Roll-In (VenaSeal SCS) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03455699?
This trial is sponsored by Medtronic Endovascular, which has 8 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03455699 being conducted?
This trial has 9 study locations across Arizona, California, Colorado, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.